RMTG Regenerative Medical Technology Group Inc.
Retail-Retail Stores, NEC · OTC · SEC CIK 1760026 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY94.3%
TTM net income YoY-155.5%
TTM EPS YoY-55.6%
Revenue 3-yr CAGR66.0%
Net income 3-yr CAGR—
Margins
Gross margin59.8%
Operating margin0.5%
Net margin-101.2%
FCF margin-6.2%
EBITDA margin4.3%
Returns
ROE—
ROA-184.4%
ROIC (approx.)—
Asset turnover1.82x
Leverage & solvency
Liabilities / assets771.0%
Debt / equity—
Current ratio0.05x
Interest coverage0.00x
Cash quality & payout
Operating cash flow / net income-0.03x
Accruals ratio-189.6%
Payout ratio—
Capex / revenue9.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.10M | $4.11M |
| Cost of revenue | $2.29M | $1.28M |
| Gross profit | $2.81M | $2.82M |
| SG&A expense | $1.12M | $798,316 |
| Operating income | -$867,162 | $81,181 |
| Interest expense | $7.45M | $5.64M |
| Income tax | -$1.64M | -$1.16M |
| Net income | -$7.81M | -$5.56M |
| EBITDA | -$586,095 | $301,740 |
| EPS (basic) | -0.62 | -0.44 |
| EPS (diluted) | -0.62 | -0.44 |
| Weighted avg. shares (diluted) | 12.63M | 12.53M |
| Balance sheet | ||
| Cash & equivalents | $956,718 | $1.17M |
| Receivables | $43,815 | $22,605 |
| Inventory | $159,277 | $10,115 |
| Current assets | $1.22M | $1.25M |
| PP&E, net | $870,759 | $451,703 |
| Goodwill | $1.68M | $1.68M |
| Intangibles | $61,464 | $159,004 |
| Total assets | $4.49M | $3.82M |
| Current liabilities | $38.13M | $28.97M |
| Total liabilities | $40.54M | $31.18M |
| Shareholders' equity | -$36.05M | -$27.36M |
| Shares outstanding | 13.14M | 12.54M |
| Cash flow statement | ||
| Operating cash flow | -$706,519 | $850,699 |
| Capital expenditure | $602,583 | $215,419 |
| Free cash flow | -$1.31M | $635,280 |
| Investing cash flow | -$602,583 | -$215,419 |
| Financing cash flow | $1.10M | — |
| Depreciation & amortization | $281,067 | $220,559 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.